Can Patients Switch to Biosimilar Aflibercept? - Quiz - MDSpire

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

  • By

  • Andrea Surnit

  • July 20, 2026

  • 3 min

Share

Original Source(s)

Can Patients Switch to Biosimilar Aflibercept?

  • by Andrea Surnit

  • July 20, 2026

Related Content

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Update on Diabetic Disease

Upfront: Monthly reflection by Editor in Chief Diana V. Do, MD.

Levels of vascular endothelial growth factor and filtration surgery outcomes in diabetic patients with acute primary angle closure